Pharmaceutical ophthalmic compositions
AssigneesNovel Drug Soultions LLC, Eye Care Northwest, Pa
InventorsJeffrey T. Liegner, John Scott Karolchyk, Bernard Covalesky, Richard Dilzer, Kalian Peters
Life of this patent
Estimating the term…
Abstract
Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.
Claims4
A pharmaceutical composition, comprising:
- (a) a therapeutically effective quantity of triamcinolone or a derivative thereof;
- (b) a therapeutically effective quantity of moxifloxacin;
- (c) a non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer having a molecular weight of the polyoxypropylene portion of about 4,000 Daltons and about a 70% polyoxyethylene content, with an overall molecular weight of between about 9,840 Daltons and about 14,600 Daltons, wherein the concentration of the non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer is between about 1 mass % and about 2 mass % of the pharmaceutical composition;
- (d) about 1% of polysorbate 80;
- and
- (e) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.